Senior Strategic Account Director, Medical Communications
Precision Medicine Group
Philadelphia, PA (Remote)
$128K/yr - $188K/yrIn-houseFull-timeSenior level7+ years exp.
2 weeks ago
Senior Director, Medical Strategy & Communications
Bothell, WA (On-site)
Salary Not AvailableFull time
Posted 3 months ago
Top 1% of applicants do these two things.
The other 99% submit and hope. You're about to do something different.
Job Description
Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
Position Overview
The Senior Director, Medical Strategy & Communications will establish a strategy to support generation and communication of scientific information. This individual will drive planning and execution of publications aligned with strategic priorities. They will lead the development and training of scientific communication materials for effective medical affairs operations, oversee establishment and growth of the medical information function, and manage medical evidence generation/ISR strategies to support external research. The position will report to the SVP, Medical Affairs and will be an integral part of the leadership team. They will be empowered to make decisions and drive results, which will require deep scientific subject matter expertise, strong business acumen, effective communication, and coaching/development skills.
Responsibilities
- Foster partnerships with senior leaders and cross functional teams to shape data. communication and engagement strategy.
- Drive planning and execution of publications.
- Lead development of scientific communication materials and training.
- Support advisory board and congress planning.
- Contribute to the Medical, Legan, and Regulatory (MLR) process.
- Manage medical information function.
- Plan and operationalize medical evidence generation activities (ISRs, etc).
Qualifications
- A minimum of 6 years' experience in biotech/pharmaceutical industry medical affairs required; 8+ years preferred.
- Oncology Medical Affairs experience is required.
- Deep expertise in medical communications and regulatory considerations.
- Strong interpersonal skills for effective communication.
- Up to 10% travel required.
Knowledge and Skills
- Demonstrated success in driving peer reviewed publications.
- Deep expertise in the evolving landscape of publications, medical communications, and medical information.
- Proven ability to develop new teams and deliver on compressed timelines.
- Strong understanding of investigator sponsored research.
- Proven ability to independently manage complex projects and communicate effectively with a wide range of internal and external stakeholders.
Washington State Pay Range
$1—$2 USD
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
